

MMP8 polymorphism is associated with susceptibility to osteonecrosis of the femoral head in a Chinese Han population

Feimeng An^{1,2,*}, Jieli Du^{2,*}, Yuju Cao³, Jianping Shi⁴, Yongchang Guo³, Tianbo Jin⁵, Jian Li³, Junyu Chen^{1,2}, Ping Li², Mei Dong², Guoqiang Wang², Jianzhong Wang²

¹Inner Mongolia Medical University, Hohhot, Inner Mongolia, China

²Department of Orthopedics and Traumatology, The Second Affiliated Hospital of Inner Mongolia University, Hohhot, Inner Mongolia, China

³Zhengzhou TCM Traumatology Hospital, Zhengzhou, Henan, China

⁴Department of TCM Diagnosis, Inner Mongolia Medical University, Hohhot, China

⁵MOE Key Laboratory of Resource Biology and Modern Biotechnology, Northwest University, Xi'an, China

*These authors contributed equally to this work and should be considered co-first authors

Correspondence to: Guoqiang Wang, email: wangguoqiangggq@163.com
Jianzhong Wang, email: wangjianzhong0503@126.com

Keywords: MMP8, single nucleotide polymorphisms, osteonecrosis of the femoral head, association study

Received: October 07, 2016

Accepted: January 09, 2017

Published: February 16, 2017

ABSTRACT

Osteonecrosis of the femoral head (ONFH) is an orthopedic refractory disease that adversely affects quality of life. Matrix metalloproteinase-8 (MMP-8) produced by the bone marrow has been implicated in the degradation of collagen during bone development. We assessed whether MMP8 polymorphisms are associated with ONFH. In a case-control study, using χ^2 tests and genetic model analyses, we genotyped 5 MMP8 single-nucleotide polymorphisms (SNPs) in 585 ONFH patients and 507 healthy control subjects in a Chinese Han population. The MMP8 rs11225394 SNP was associated with an increased risk of ONFH in an allele model (OR=1.34; 95% CI, 1.003-1.786, P=0.047). In addition, rs11225394 was associated with an increased risk of ONFH in a dominant model (OR =1.39, 95% CI, 1.02-1.89, P=0.036), over-dominant model (OR=1.39, 95% CI, 1.02-1.89, P=0.038), and log-additive model (OR =1.36, 95% CI, 1.01-1.84, P=0.039). After adjusting for age and gender, rs11225394 was associated with ONFH in a dominant (OR =1.44, 95% CI, 1.05-1.96, P=0.023), over-dominant (OR =1.44, 95% CI, 1.05-1.98, P=0.022), and log-additive model (OR =1.40, 95% CI, 1.04-1.90, P=0.027). These results provide the first evidence that MMP8 SNP at the rs11225394 locus is associated with the increased risk of ONFH in Chinese Han population.

INTRODUCTION

Osteonecrosis of the femoral head (ONFH) is an intractable bone disease resulting in considerable loss of function of common hip joint. Without treatment, osteonecrosis usually progresses to femoral head collapse and subsequent degenerative arthritis of the hip joint [1]. Despite preserving and surgical treatments, morbidity and disability from osteonecrosis in the Chinese Han population continue to rise. Therefore, early detection is crucial to improve outcomes and patients quality of life. Since early detection of ONFH remains difficult due to the lack of early clinical symptoms, there is an urgent

need to elucidate the etiology and pathogenic mechanisms underlying ONFH.

Bone marrow mesenchymal stem cells (BMSCs) have the potential to differentiate into osteoblasts of bone-building, and osteoclasts of bone-destroying. In general, the amount of bone removed by the osteoclasts, and the amount of bone formed by the osteoblasts, maintain a constant bone mass throughout life. One of the mechanisms of non-traumatic ONFH is the increased bone resorption and/or decreased bone formation [2-4]. Osteoblasts are involved in bone matrix degradation and synthesis of collagen type I, a specific type of collagen that is synthesized by osteoblasts in bone tissue, and plays

an important role in osteoblastic differentiation of BMSCs [5–8]. In addition, collagen type I is a major component of the bone extracellular matrix, and correlates with bone resorption [9, 10]. Thus, it has been suggested that collagen type I may be associated with an increased risk of ONFH.

The matrix metalloproteinase (MMP) family comprises 23 protein members, which have the ability to degrade virtually all structural components of the extracellular matrix. MMPs are thought to be the key regulators of tissue degradation and remodeling [11, 12]. Furthermore, MMPs are considered to play an important role in the regulation of osteogenesis and bone remodeling during embryogenesis, adolescence, and bone healing [13]. Matrix metalloproteinase-8 (also known as neutrophil collagenase and collagenase-2), encoded by *MMP8*, is produced predominantly in the bone marrow, and expressed in neutrophils and macrophages [14]. Up to now, two main roles of MMP-8 have been identified. First, MMP-8 can cleave the triple helix structure of native collagen, thus initiating the first steps of collagen degradation [15]. Second, since MMP-8 is highly expressed in neutrophils, increased expression and activity of MMP-8 can reflect neutrophils (associated with the initial inflammatory stages of wound repair) in the fluids of healing wounds, and can influence the wound healing [14, 16]. MMP-8 has the substrate specificity for interstitial collagen type I disruption [17]. In addition, increased expression of MMP-8 can promote osteoclast differentiation and activity [18]. Thus, we hypothesized that MMP-8 plays an important role in the pathogenesis of ONFH.

Recent studies have indicated that single nucleotide polymorphisms (SNPs) are associated with an increased risk of ONFH [19–22]. The polymorphisms of *MMP8* have been investigated in many diseases. In this case-control study, we genotyped five SNPs in *MMP8* (rs3740938, rs2012390, rs1940475, rs11225394, and rs11225395) that have been associated with refractive error [23], sepsis [24], atherosclerosis [25], thoracic aortic dissection [26], bladder cancer [27], breast cancer [28], and steroid-induced ONFH [29]. We performed a comprehensive association analysis that indicates the association between these SNPs and ONFH risk in Chinese Han population.

RESULTS

A total of 1092 participants (585 patients with ONFH and 507 healthy controls) were genotyped. The ONFH cases and healthy controls were matched in sex ($P=0.293$). Primers and PCR product sequences are shown in Table 1. Basic characteristics, including gender and age, are listed in Table 2. Table 3 summarizes the basic characteristics of SNPs in the study specimens. None of the tSNPs that were excluded deviated from Hardy–Weinberg equilibrium (HWE). The χ^2 test was used

to compare the differences in frequency distributions of alleles between cases and controls. One tSNP was associated with an increased risk of developing ONFH: rs11225394 in *MMP8* (OR=1.34; 95% CI, 1.003–1.786, $P=0.047$). The other SNPs did not correlate with the risk of ONFH.

Next, we assumed that the minor allele of each tSNP was a risk factor, and we assessed the association between these SNPs and ONFH risks using five genetic models (codominant, dominant, recessive, over-dominant, and log-additive) by unconditional logistic-regression analysis. Our analyses in Table 4 showed that the genotype “T/C” of rs11225394 in the *MMP8* gene was associated with an increased risk of ONFH in the dominant model before (OR =1.39, 95% CI, 1.02–1.89, $P=0.036$) and after (adjusted OR =1.44, 95% CI, 1.05–1.96, $P=0.023$) adjustment. Similarly, in the over-dominant model, rs11225394 also exhibited a significant association with the ONFH risk before (OR=1.39, 95% CI, 1.02–1.89, $P=0.038$) and after (OR =1.44, 95% CI, 1.05–1.98, $P=0.022$) adjustment. In addition, in the log-additive model, the T/C genotype of rs11225394 also conferred an increased risk before (OR =1.36, 95% CI, 1.01–1.84, $P=0.039$) and after (OR =1.40, 95% CI, 1.04–1.90, $P=0.027$) adjustment for age and sex.

DISCUSSION

In this study, five SNPs in the *MMP8* gene were examined in 1092 subjects to determine whether they were associated with the risk of ONFH in the Chinese Han population. The most valuable finding is that the rs11225394 polymorphism in *MMP8* showed a significant association with an increased risk of ONFH occurrence. We are the first to demonstrate an association between this locus and ONFH susceptibility.

Rs11225394 is located in the intron (boundary) region of the *MMP8* gene. Morgan *et al.* [30] has demonstrated that rs11225394 is associated with increased risk of ulcerative colitis. In addition, rs11225394 has been associated with the refractive error [31]. However, rs11225394 did not correlate with the risk of steroid-induced ONFH in the population of northern China and rs3740938, rs3740938, rs1940475, rs11225395 were associated with an increased risk of steroid-induced ONFH in the population of northern China [29]. This is inconsistent with our results, and this inconsistency may be explained by the genetic differences between steroid-induced ONFH and other forms of ONFH. These data illustrate the complexity of the mechanisms and multiple interacting networks involved in the SNPs, which may promote ONFH.

Like most MMPs, MMP-8 is secreted as an inactive pro-enzyme, which can be converted into an active protease [32]. The expression of MMP-8 is related to inflammatory cytokines, growth factors, and hormones [33]. In terms of orthopedic diseases and related

Table 1: Primers Used for this Study

SNP_ID	1st-PCR	2nd-PCR	UEP_SEQ
rs3740938	ACGTTGGATGGTCAGTAAGAGGAATCAAAG	ACGTTGGATGTGACATTTGATGCTATCAC	GATGCTATCACCACACT
rs2012390	ACGTTGGATGACTGTTTCTAGGTCACACCC	ACGTTGGATGTCAGGGAGAGGAAGCAATTC	GAAGCAAATGTGAGGAAGAT
rs1940475	ACGTTGGATGTTTGGGTTGAATGTGACGGG	ACGTTGGATGTAAAACCACCACTGTCAGGC	CTCCACAGCGAGGCTTTT
rs11225394	ACGTTGGATGCAATCTCAAATAATCACCC	ACGTTGGATGTTAGGAAATAGTGTGGGTTG	AGTGTGGGTTGTTTCTCTT
rs11225395	ACGTTGGATGAGAGCTGCTGCTCCACTATG	ACGTTGGATGGTTTAGAGAGACTGAGCTGG	GCTGAGCTGGGAGCTACTATA

Table 2: Characteristics of cases and controls in this study

Various	cases n=585	Controls n=507	P value
Sex			0.293 ^a
male	472(80.7%)	396(78.1%)	
female	113(19.3%)	111(21.9%)	
Age, year (mean ± SD)	42.61±12.951	47.43±9.739	< 0.001 ^b

$p \leq 0.05$ indicates statistical significance

^a Two-sided Chi-squared test

^b Independent samples *t* test

Table 3: Allele frequencies in cases and controls and odds ratio estimates for ONFH

SNP	Gene	Locus	Alleles (A/B)	MAF		HWE p^a value	ORs	95%CI	p^b value
				Case	Control				
rs3740938	MMP8	11q22.2	A/G	0.243	0.235	0.621	1.04	0.856-1.270	0.680
rs2012390	MMP8	11q22.2	G/A	0.276	0.276	0.912	1.00	0.827-1.204	0.981
rs1940475	MMP8	11q22.2	T/C	0.387	0.369	0.775	1.08	0.909-1.286	0.378
rs11225394	MMP8	11q22.2	T/C	0.112	0.086	0.563	1.34	1.003-1.786	0.047*
rs11225395	MMP8	11q22.2	A/G	0.379	0.360	0.773	1.08	0.910-1.290	0.367

SNP single nucleotide polymorphism, HWE Hardy-Weinberg equilibrium, OR odds ratio, 95% CI 95% confidence interval, MAF minor allele frequency

* $p \leq 0.05$ indicates statistical significance

^a p was calculated by exact test

^b p was calculated by Pearson Chi-squared test

disorders, MMP-8 is expressed in cells of the osteoblastic lineage, the mesenchymal condensation, periosteal cells, osteoblasts, osteocytes, muscle cells, and chondrocytes. The possible reason might be that MMP-8 may be involved in remodeling of collagenous ECMs during embryonic bone development [34]. In periodontitis, pro-inflammatory cytokines can stimulate gingival fibroblasts to secrete MMP-8, thereby enhancing ECM and basement membrane breakdown, which is one of the possible mechanisms causing periodontitis [18]. In osteosarcoma, *MMP8* is negatively regulated by microRNA-539 through a special binding site in the *MMP8* 3'-UTR, which may

inhibit osteosarcoma cell proliferation and migration [35]. In carious dentin of primary teeth, a strong expression of MMP-8 was also observed in both active caries lesion and sealing infected caries dentin [36]. In arthritis, lack of MMP-8 is accompanied by exacerbated joint inflammation and bone erosion, indicating that MMP-8 might have a protective role in arthritis [37]. However, there is a limited evidence for a direct function of MMP-8 in orthopedic diseases. Currently, the relationship between rs11225394 polymorphism and *MMP8* gene expression/function in ONFH patients is not clear. Further studies are required to characterize the function of *MMP8* and elucidate the

Table 4: Genotypic model analysis of relationship between SNPs and ONFH risk

Model	Genotype	Group=control	Group=Hormone	Without Adjustment		With Adjustment		AIC	BIC
				OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value		
Codominant	C/C	405 (83.2%)	456 (78.1%)	1		1			
	T/C	80 (16.4%)	125 (21.4%)	1.39 (1.02-1.89)	0.11	1.44 (1.05-1.98)	0.073	1437.9	1462.8
	T/T	2 (0.4%)	3 (0.5%)	1.33 (0.22-8.01)		1.14 (0.18-7.08)			
Dominant	C/C	405 (83.2%)	456 (78.1%)	1	0.036	1	0.023	1435.9	1455.9
	T/C-T/T	82 (16.8%)	128 (21.9%)	1.39 (1.02-1.89)		1.44 (1.05-1.96)			
Recessive	C/C-T/C	485 (99.6%)	581 (99.5%)	1	0.8	1	0.95	1441.1	1461
	T/T	2 (0.4%)	3 (0.5%)	1.25 (0.21-7.52)		1.07 (0.17-6.61)			
Overdominant	C/C-T/T	407 (83.6%)	459 (78.6%)	1	0.038	1	0.022	1435.9	1455.8
	T/C	80 (16.4%)	125 (21.4%)	1.39 (1.02-1.89)		1.44 (1.05-1.98)			
Log-additive	---	---	---	1.36 (1.01-1.84)	0.039	1.40 (1.04-1.90)	0.027	1436.3	1456.2

**p* ≤ 0.05 indicates statistical significance

p values were calculated by Wald test by unconditional logistic regression adjusted for age and gender

mechanisms underlying the association between *MMP8* and ONFH susceptibility.

Our study provides the first evidence of the association between rs11225394 in *MMP8* and the risk of ONFH. Although this study had a sufficient statistical power, there were some intrinsic limitations. First, the participants' ethnicity was limited to the Han Chinese population. Thus, further analysis is needed to determine whether current conclusions are applicable also to other ethnicities. Second, the participant cases were enrolled in the same hospital, so selection bias cannot be excluded and the subjects might not be representative of the general population. However, this bias was not meaningful because the samples did not differ in geographical distributions or genotype frequencies. Finally, even though we discovered the association between rs11225394 and ONFH susceptibility, we did not elucidate causal mechanisms.

Together, our results provide the first evidence regarding the relationship between *MMP8* and the risk of ONFH. We believe that our results will encourage further studies to characterize the function of *MMP8* and elucidate the underlying mechanisms of *MMP8* polymorphisms conferring susceptibility to ONFH.

MATERIALS AND METHODS

Study participants and data collection

In this case-control study, we recruited participants among Chinese population including patients with confirmed ONFH and with the mean age of 42.61±12.951, as well as healthy controls with the mean age of 47.43±9.739. These cases were recruited from the Zhengzhou Traditional Chinese Medicine (TCM)

Traumatology Hospital between January 2013 and May 2015. Control subjects were genetically unrelated Chinese residents who were enrolled from the Zhengzhou Medical Center in Henan Province. All participants were Han Chinese. A standard epidemiologic questionnaire was used to collect personal data. Informed consent was obtained from all participants of the study. The protocols for were approved by the Zhengzhou TCM Traumatology Hospital Human Research Committee for Approval of Research Involving Human Subjects.

Inclusion and exclusion criteria

The diagnosis of ONFH was defined according to the following criteria: (1) clinical ONFH manifestations, such as pain and activity limitation of hip, sick side lower limb muscle atrophy. (2) MRI and plain radiography changes can yield the most accurate diagnosis like high density shadows of femoral head, hip joint narrowness and bumpiness, or joint surface rupture. (3) All patients had a physical examination. Those who met the criteria for ONFH were selected. Patients who were diagnosed by MRI without abnormalities on plain radiography were also selected for this study. Patients with an explicit history of direct trauma or with possible combined causes were excluded. Those who had a chronic metabolic disorder of heart, kidney, or liver were also excluded.

All control subjects were healthy. Selection criteria were the following: (1) No hip pain; (2) Anteroposterior and frog-leg lateral pelvic radiographs did not show any lesions; (3) Subjects with a long term history of alcohol and steroid use were excluded; and (4) All individuals related to the enrolled patients were excluded from the control group.

Selection of single-nucleotide polymorphisms and genotyping methods

All five primers from one gene were designed to amplify fragments of rs3740938, rs3740938, rs1940475, rs11225394, and rs11225395. In our ongoing case-control study, 5 ml of peripheral blood were drawn into coded sodium citrate-coated tubes from each participant and stored at -80°C after centrifugation. Extraction of DNA from whole blood samples was performed using the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd. Xi'an City, China) and the DNA concentration was measured by NanoDrop 2000 spectrophotometer. The Multiplexed SNP MassEXTENDED assay was designed by Sequenom MassARRAY Assay Design 3.0 Software. Genotyping was performed using the Sequenom MassARRAY RS1000 system according to the manufacture's protocol. Data management and analysis were performed using Sequenom Typer 4.0 Software.

Statistical analysis

Data were analyzed by the SPSS version 18.0 statistical software (SPSS, Chicago, IL) and Microsoft Excel. We performed the 2-side chi-square tests to estimate the genotype frequencies of case and control individuals; a P-value of less than 0.05 was considered statistically significant. A Fisher's exact test was used to assess the departure of each SNP frequency from Hardy-Weinberg equilibrium (HWE) in the control subjects. ORs and 95% CIs were determined using unconditional logistic regression analysis with adjustments for age and sex. The relation between the *MMP8* gene and the risk of ONFH was tested in dominant and recessive models and also codominant, over-dominant and log-additive effects. We used Akaike's Information Criterion and Bayesian Information Criterion to estimate the best-fit model for each SNP.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (No. 81160228, 81260284, 81660378). We thank all patients and participants in this study.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Troy KL, Lundberg HJ, Conzemius MG, Brown TD. Habitual hip joint activity level of the penned EMU (*Dromaius novaehollandie*). *Iowa Orthop J*. 2007; 27:17-23.

2. Carrington JL. Aging bone and cartilage: cross-cutting issues. *Biochem Biophys Res Commun*. 2005; 328:700-8. doi: 10.1016/j.bbrc.2004.12.041.
3. Kim MH, Cho GW, Huh YM, Kim SH. Transduction of human EPO into human bone marrow mesenchymal stromal cells synergistically enhances cell-protective and migratory effects. *Mol Biol (Mosk)*. 2010; 44:656-63.
4. Zhang L, Zheng W, Wang Y, Wang Y, Huang H. Human bone marrow mesenchymal stem cells support the derivation and propagation of human induced pluripotent stem cells in culture. *Cell Reprogram*. 2013; 15:216-23. doi: 10.1089/cell.2012.0064.
5. Mittag F, Falkenberg EM, Janczyk A, Gotze M, Felka T, Aicher WK, Kluba T. Laminin-5 and type I collagen promote adhesion and osteogenic differentiation of animal serum-free expanded human mesenchymal stromal cells. *Orthop Rev (Pavia)*. 2012; 4:e36. doi: 10.4081/or.2012.e36.
6. Salaszyk RM, Klees RF, Boskey A, Plopper GE. Activation of FAK is necessary for the osteogenic differentiation of human mesenchymal stem cells on laminin-5. *J Cell Biochem*. 2007; 100:499-514. doi: 10.1002/jcb.21074.
7. Grzibovskis M, Urtane I, Pilmane M, Jankovska I. Specific signaling molecule expressions in the interradicular septum in different age groups. *Stomatologija*. 2011; 13:81-6.
8. Jonitz-Heincke A, Lochner K, Schulze C, Pohle D, Pustlauk W, Hansmann D, Bader R. Contribution of human osteoblasts and macrophages to bone matrix degradation and proinflammatory cytokine release after exposure to abrasive endoprosthetic wear particles. *Mol Med Rep*. 2016; 14:1491-500. doi: 10.3892/mmr.2016.5415.
9. Syggelos SA, Aletas AJ, Smirlaki I, Skandalis SS. Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome. *Biomed Res Int*. 2013; 2013:230805. doi: 10.1155/2013/230805.
10. Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. *Am J Clin Pathol*. 1981; 75:816-21.
11. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc Res*. 2006; 69:562-73. doi: 10.1016/j.cardiores.2005.12.002.
12. Xue M, Le NT, Jackson CJ. Targeting matrix metalloproteases to improve cutaneous wound healing. *Expert Opin Ther Targets*. 2006; 10:143-55. doi: 10.1517/14728222.10.1.143.
13. Ortega N, Behonick D, Stickens D, Werb Z. How proteases regulate bone morphogenesis. *Ann N Y Acad Sci*. 2003; 995:109-16.
14. Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. *Cytokine Growth Factor Rev*. 2006; 17:217-23. doi: 10.1016/j.cytogfr.2006.04.001.

15. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? *Matrix Biol.* 1997; 15:511-8.
16. Nwomeh BC, Liang HX, Cohen IK, Yager DR. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. *J Surg Res.* 1999; 81:189-95. doi: 10.1006/jsre.1998.5495.
17. Hastly KA, Jeffrey JJ, Hibbs MS, Welgus HG. The collagen substrate specificity of human neutrophil collagenase. *J Biol Chem.* 1987; 262:10048-52.
18. Pandruvada SN, Gonzalez OA, Kirakodu S, Gudhimella S, Stromberg AJ, Ebersole JL, Orraca L, Gonzalez-Martinez J, Novak MJ, Huja SS. Bone biology-related gingival transcriptome in ageing and periodontitis in non-human primates. 2016; 43:408-17. doi: 10.1111/jcpe.12528.
19. Kim TH, Bae SC, Lee SH, Kim SY, Baek SH. Association of Complement Receptor 2 Gene Polymorphisms with Susceptibility to Osteonecrosis of the Femoral Head in Systemic Lupus Erythematosus. 2016; 2016:9208035. doi: 10.1155/2016/9208035.
20. Li Y, Wang Y, Guo Y, Wang Q, Ouyang Y, Cao Y, Jin T, Wang J. OPG and RANKL polymorphisms are associated with alcohol-induced osteonecrosis of the femoral head in the north area of China population in men. *Medicine (Baltimore).* 2016; 95:e3981. doi: 10.1097/md.0000000000003981.
21. Wang Y, Cao Y, Li Y, Guo Y, Wang Q, Yang M, Zhang N, Jin T, Wang J. Genetic association of the ApoB and ApoA1 gene polymorphisms with the risk for alcohol-induced osteonecrosis of femoral head. *Int J Clin Exp Pathol.* 2015; 8:11332-9.
22. Assouline-Dayana Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. *Semin Arthritis Rheum.* 2002; 32:94-124.
23. Schache M, Baird PN. Assessment of the association of matrix metalloproteinases with myopia, refractive error and ocular biometric measures in an Australian cohort. *PLoS One.* 2012; 7:e47181. doi: 10.1371/journal.pone.0047181.
24. 31st International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium. 22-25 March 2011. Abstracts. *Crit Care.* 2011; 15 Suppl 1:S1-199.
25. Laxton RC, Hu Y, Duchene J, Zhang F, Zhang Z, Leung KY, Xiao Q, Scotland RS, Hodgkinson CP, Smith K, Willeit J, Lopez-Otin C, Simpson IA, et al. A role of matrix metalloproteinase-8 in atherosclerosis. *Circ Res.* 2009; 105:921-9. doi: 10.1161/circresaha.109.200279.
26. Wang XZ, Du XM, Jing QM, Li XX, Gu RX, Wang J, Han YL. Impact of matrix metalloproteinase-8 gene variations on the risk of thoracic aortic dissection in a Chinese Han population. *Mol Biol Rep.* 2013; 40:5953-8. doi: 10.1007/s11033-013-2704-2.
27. Wieczorek E, Reszka E, Wasowicz W, Grzegorzczak A, Konecki T, Sosnowski M, Jablonowski Z. MMP7 and MMP8 genetic polymorphisms in bladder cancer patients. *Cent European J Urol.* 2014; 66:405-10. doi: 10.5173/ceju.2013.04.art3.
28. Beeghly-Fadiel A, Zheng W, Lu W, Long J, Zheng Y, Cai H, Gu K, Chen Z, Cai Q, Gao YT, Shu XO. Replication study for reported SNP associations with breast cancer survival. *J Cancer Res Clin Oncol.* 2012; 138:1019-26. doi: 10.1007/s00432-012-1174-6.
29. Du J, Jin T, Cao Y, Chen J, Guo Y, Sun M, Li J, Zhang X, Wang G, Wang J. Association between genetic polymorphisms of MMP8 and the risk of steroid-induced osteonecrosis of the femoral head in the population of northern China. *Medicine (Baltimore).* 2016; 95:e4794. doi: 10.1097/md.0000000000004794.
30. Morgan AR, Han DY, Lam WJ, Triggs CM, Fraser AG, Barclay M, Gearry RB, Meisner S, Stokkers P, Boeckxstaens GE, Ferguson LR. Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. *Hum Immunol.* 2011; 72:1117-27. doi: 10.1016/j.humimm.2011.08.011.
31. Wojciechowski R, Bailey-Wilson JE, Stambolian D. Association of matrix metalloproteinase gene polymorphisms with refractive error in Amish and Ashkenazi families. *Invest Ophthalmol Vis Sci.* 2010; 51:4989-95. doi: 10.1167/iovs.10-5474.
32. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res.* 2003; 92:827-39. doi: 10.1161/01.res.0000070112.80711.3d.
33. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. *J Biol Chem.* 1999; 274:21491-4.
34. Sasano Y, Zhu JX, Tsubota M, Takahashi I, Onodera K, Mizoguchi I, Kagayama M. Gene expression of MMP8 and MMP13 during embryonic development of bone and cartilage in the rat mandible and hind limb. *J Histochem Cytochem.* 2002; 50:325-32.
35. Jin H, Wang W. MicroRNA-539 suppresses osteosarcoma cell invasion and migration *in vitro* and targeting Matrix metalloproteinase-8. *Int J Clin Exp Pathol.* 2015; 8:8075-82.
36. Chibinski AC, Gomes JR, Camargo K, Reis A, Wambier DS. Bone sialoprotein, matrix metalloproteinases and type I collagen expression after sealing infected caries dentin in primary teeth. *Caries Res.* 2014; 48:312-9. doi: 10.1159/000355302.
37. Garcia S, Forteza J, Lopez-Otin C, Gomez-Reino JJ, Gonzalez A, Conde C. Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. *Arthritis Res Ther.* 2010; 12:R224. doi: 10.1186/ar3211.